How these generic drugs stocks are faring? — Medicines Co., Ironwood Pharma, Pacira Pharma, and Supernus Pharma.
Stock-Callers.com has issued research reports on: The Medicines Co., Ironwood Pharmaceuticals Inc., Pacira Pharmaceuticals Inc., and Supernus Pharmaceuticals Inc. According to Research and Markets’ report titled, “Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry 2017,” the U.S. is the biggest Generic Drugs market in the world, with nearly 80% of prescriptions written in the country just for generics.
Medicines Co.
Parsippany, New Jersey-based The Medicines Co.’s (MDCO) shares recorded a trading volume of 1.05 million shares last Friday. The stock finished the trading session 1.52% higher at $49.32. The company’s shares have surged 41.24% over the previous three months and 45.32% since the start of this year. The stock is trading above its 200-day moving average by 20.89%. Furthermore, shares of MDCO, which provides medicines for patients in acute and intensive care hospitals worldwide, have a Relative Strength Index (RSI) of 41.80.
On April 26th, 2017, MDCO and Alnylam Pharmaceuticals, Inc. announced that the former has agreed with the U.S. Food and Drug Administration (FDA) on plans for the Phase III clinical program for inclisiran, which is designed to support the submission of a New Drug Application. MDCO has received final, End-of-Phase II meeting minutes from the FDA.
Ironwood Pharma
On Friday, Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc.’s stock ended the session 0.37% lower at $16.32. A total volume of 736,441 shares was traded. The company’s shares have gained 16.82% over the previous three months and 6.74% on an YTD basis. The stock is trading 6.86% above its 200-day moving average. Moreover, shares of Ironwood Pharma, which engages in the research, development, and commercialization of human therapeutic products, have an RSI of 47.70.
On April 07th, 2017, research firm Mizuho reiterated its ‘Buy’ rating on the company’s stock with an increase of the target price from $21 a share to $22 a share.
On April 24th, 2017, Ironwood Pharma announced that it will host its Q1 2017 investor update conference call and webcast at 8:30 a.m. ET on Monday, May 08th, 2017. The webcast may be accessed under the Investors section of the company’s website.
Pacira Pharma
Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.’s stock ended the day 1.04% higher at $48.55 with a total trading volume of 903,166 shares. The company’s shares have gained 2.00% in the last month, 30.34% over the previous three months, and 50.31% on an YTD basis. The stock is trading 4.58% and 23.37% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 59.09.
On April 13th, 2017, research firm RBC Capital Markets initiated an ‘Outperform’ rating on the company’s stock, with a target price of $58 per share.
On April 27th, 2017, Pacira Pharma announced that it will report its Q1 financial results before the open of the U.S. markets on Thursday, May 04th, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call will be Dave Stack, Chairman and CEO, and other members of the company’s senior management team.
Supernus Pharma
Shares in Rockville, Maryland-based Supernus Pharmaceuticals Inc. recorded a trading volume of 378,057 shares. The stock ended Friday’s session 1.81% lower at $32.60. The company’s shares have gained 6.02% in the last month, 25.38% over the previous three months, and 29.11% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 11.35% and 31.96%, respectively. Furthermore, shares of Supernus Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system diseases in the US, have an RSI of 61.94.
On April 26th, 2017, Supernus Pharma announced that it expects to report the financial results for Q1 2017 after 5:00 p.m. ET on Tuesday, May 09th, 2017. Jack Khattar, President and CEO, and Greg Patrick, CFO, will host a conference call to present Q1 2017 results on Wednesday, May 10th, 2017, at 9:00 a.m. ET.
(Source: PR Newswire)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
